How to define and manage borderline resectable pancreatic cancer

Surg Clin North Am. 2013 Jun;93(3):663-74. doi: 10.1016/j.suc.2013.02.005. Epub 2013 Mar 27.

Abstract

Historically, borderline resectable (BLR) pancreatic cancer has had many definitions, which has made interpretation of treatment data and outcomes difficult. Advances in imaging, surgical technique, and the potential benefit of neoadjuvant therapy have emphasized the need for uniform classification. Despite recent efforts to provide a clearer definition, prospective randomized trials are lacking in the literature. This article reviews current definitions, treatment sequences, outcomes, and prognostic factors associated with BLR pancreatic cancer. Further clarification and consensus on the definition of BLR pancreatic cancer will allow for further data collection and cooperation in future efforts to make progress and standardize treatment.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Chemoradiotherapy, Adjuvant
  • Chemotherapy, Adjuvant
  • Humans
  • Neoadjuvant Therapy
  • Pancreatectomy*
  • Pancreatic Neoplasms / diagnostic imaging
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery*
  • Pancreatic Neoplasms / therapy
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antineoplastic Agents